Scion Life Sciences, a new venture firm, has been launched by industry veterans with a fund of $310 million aimed at backing new biotech startups, as reported by Gwendolyn Wu. The founders of Scion Life Sciences, which includes one of the co-founders of the radiopharma success story RayzeBio, intend to build the next independent, scalable biotech companies, potentially mirroring the success of established entities like Vertex or Regeneron. The firm is looking to move away from what its founders consider the 'artifacts' of traditional venture investing.
Venture firm Scion Life Sciences launches with $310M to back new #biotechs https://t.co/jKyTQYjncU by @gwendolynawu
The need-to-know in biotech this morning: The arrival of Scion Life Sciences, GLP-1 drug panic and the weight of expectations on Eli Lilly. https://t.co/MIqZZf2gGx
The need-to-know in biotech this morning: —The arrival of Scion Life Sciences —GLP-1 drug panic —The weight of expectations on Eli Lilly https://t.co/a9UJ02LFiY
Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences. https://t.co/7JqBQDKqWx
A new biotech VC firm is eschewing some of what its founders call the "artifacts" of venture investing, in the hopes of building the next independent, scalable biotech like Vertex or Regeneron. https://t.co/2WNKgTHLJS Scion Life Sciences
Industry veterans launch new biotech VC fund with $310M https://t.co/22MbL8RmVh
Venture firm Scion Life Sciences launches with $310M to back new #biotechs https://t.co/57ivumAtjg by @gwendolynawu #startups